An interventional study of bitter melon peptides in Diabetes, sponsored by Changhua Christian Hospital. Not yet recruiting. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by Changhua Christian Hospital · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to learn the potential of bitter melon peptides in stabilizing blood glucose in diabetic adults. It will also learn about the effects of bitter melon peptides on metabolic parameters. The main questions it aims to answer are:
Participants will:
11,089 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's planned enrollment of 160 is above the median of 80 across 8,491 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Changhua Christian Hospital is the lead sponsor of 76 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:Participants were diagnosed with type 2 DM based on criteria recommended by the American Diabetes Association and required to have fasting plasma glucose of ≥126 mg/dl or an HbA1c of
≥ 6.5%, as measured on two separate occasions
Exclusion Criteria:cancer, active liver disease, current pregnancy , acute illness and autoimmune thyroid disease.
Bitter melon peptide contains various active substances such as bitter melon saponins and bitter melon polysaccharides.
Dietary Supplement: bitter melon peptides
The placebo capsule containing microcrystalline cellulose. The placebo is identical in appearance, color, and dosage schedule to the intervention product, but does not contain any active ingredients.
Dietary Supplement: bitter melon peptides
Momordica charantia extract
glycemic variability
mean amplitude of glucose excursions and coefficient of variation, using CGM
Time frame: From enrollment (day0) to day7
glycemic control
Glycated hemoglobulin A1C
Time frame: From enrollment (day0) to the end (day84)
metabolic indicator
C-peptide
Time frame: From enrollment (day0) to the end (day84)
No study locations are listed for this record.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Changhua Christian Hospital